MA31400B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA31400B1 MA31400B1 MA32385A MA32385A MA31400B1 MA 31400 B1 MA31400 B1 MA 31400B1 MA 32385 A MA32385 A MA 32385A MA 32385 A MA32385 A MA 32385A MA 31400 B1 MA31400 B1 MA 31400B1
- Authority
- MA
- Morocco
- Prior art keywords
- organic compounds
- formula
- disorders
- compound
- tautomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un composé de formule (i) ou ses tautomères, ses stéréoisomères, ses solvates ou ses sels pharmaceutiquement acceptables. Dans la formule (i), m1, m2, l1, l2, w1, w2, x1, x2, y1, y2, a, r5 et r5a sont tels que définis dans le présent document. Le composé selon l'invention est destiné au traitement de troubles qui peuvent être traités par le blocage d'un canal sodium épithélial, notamment de troubles qui bénéficient de l'hydratation mucosale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07107654 | 2007-05-07 | ||
PCT/EP2008/055497 WO2008135557A1 (fr) | 2007-05-07 | 2008-05-05 | Composés organiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31400B1 true MA31400B1 (fr) | 2010-05-03 |
Family
ID=38581916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32385A MA31400B1 (fr) | 2007-05-07 | 2009-11-30 | Composes organiques |
Country Status (32)
Country | Link |
---|---|
US (1) | US8318935B2 (fr) |
EP (2) | EP2332933A1 (fr) |
JP (1) | JP5244904B2 (fr) |
KR (1) | KR20100005730A (fr) |
CN (1) | CN101687851B (fr) |
AR (1) | AR066458A1 (fr) |
AT (1) | ATE499363T1 (fr) |
AU (1) | AU2008248598B2 (fr) |
BR (1) | BRPI0811562A2 (fr) |
CA (1) | CA2685546A1 (fr) |
CL (1) | CL2008001301A1 (fr) |
CO (1) | CO6290667A2 (fr) |
CR (1) | CR11091A (fr) |
DE (1) | DE602008005140D1 (fr) |
EA (1) | EA200901489A1 (fr) |
EC (1) | ECSP099718A (fr) |
ES (1) | ES2361595T3 (fr) |
GT (1) | GT200900289A (fr) |
HK (1) | HK1141285A1 (fr) |
HN (1) | HN2009003214A (fr) |
IL (1) | IL201828A0 (fr) |
MA (1) | MA31400B1 (fr) |
MX (1) | MX2009012077A (fr) |
NZ (1) | NZ580737A (fr) |
PE (1) | PE20090733A1 (fr) |
PL (1) | PL2155721T3 (fr) |
PT (1) | PT2155721E (fr) |
SV (1) | SV2009003406A (fr) |
TN (1) | TN2009000469A1 (fr) |
TW (1) | TWI351402B (fr) |
WO (1) | WO2008135557A1 (fr) |
ZA (1) | ZA200907491B (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
KR101654549B1 (ko) | 2008-02-26 | 2016-09-07 | 패리온 사이언스 인코퍼레이티드 | 다중방향족 나트륨 채널 차단제 |
KR20110085768A (ko) | 2010-01-21 | 2011-07-27 | 삼성전자주식회사 | Cmos 이미지 센서, 상기 이미지 센서의 데이터 리드아웃 방법, 및 상기 이미지 센서를 포함하는 전자 시스템 |
US8372845B2 (en) * | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
US9050339B2 (en) | 2010-09-17 | 2015-06-09 | Novartis Ag | Pyrazine derivatives as ENaC blockers |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
CN104024244B (zh) * | 2011-11-02 | 2016-09-14 | 勃林格殷格翰国际有限公司 | 杂环化合物、含有所述化合物的药物及其用途和其制备方法 |
WO2013064451A1 (fr) * | 2011-11-02 | 2013-05-10 | Boehringer Ingelheim International Gmbh | Nouveau procédé pour la préparation d'acylguanidines et d'acylthiourées |
US8859559B2 (en) * | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
WO2013106485A2 (fr) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Régions déterminant la complémentarité ultralongues et utilisations associées |
WO2013174757A1 (fr) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Amines tertiaires, médicaments contenant lesdites amines, leur utilisation et leurs procédés de préparation |
EP2897940B1 (fr) | 2012-09-24 | 2019-05-01 | Boehringer Ingelheim International GmbH | Composés hétérocycliques, médicaments contenant ces composés, leur utilisation et procédés de leur préparation |
AU2013337730B2 (en) | 2012-11-02 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of CFTR mediated diseases |
AU2013363215B2 (en) | 2012-12-17 | 2018-03-01 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
EP3150585A1 (fr) | 2012-12-17 | 2017-04-05 | Parion Sciences, Inc. | Dérivés de carboxamide de chloro-pyrazine avec une activité de blocage de canal de sodium épithélial |
JP6353032B2 (ja) * | 2013-04-30 | 2018-07-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法 |
WO2015003083A1 (fr) * | 2013-07-02 | 2015-01-08 | The California Institute For Biomedical Research | Composés destinés au traitement de la mucosviscidose |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
UY36034A (es) | 2014-03-18 | 2015-09-30 | Astrazeneca Ab | Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos |
CN106102724A (zh) | 2014-03-27 | 2016-11-09 | 诺华股份有限公司 | 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系 |
GB201412545D0 (en) * | 2014-07-15 | 2014-08-27 | Univ Manchester The And Manchester Metropolitan University | Enzymatic processes and uses |
CN107405505A (zh) * | 2015-01-07 | 2017-11-28 | 加州生物医学研究所 | 用于治疗囊性纤维化的化合物 |
EP3245202B1 (fr) * | 2015-01-12 | 2020-03-11 | Boehringer Ingelheim International GmbH | Composés de benzimidazolium tétrasubstitué utiles pour le traitement de maladies respiratoires |
US10155749B2 (en) * | 2015-01-12 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
JP6667538B2 (ja) * | 2015-01-12 | 2020-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療に有用な置換ベンズイミダゾリウム化合物 |
US10291868B2 (en) * | 2016-01-29 | 2019-05-14 | SK Hynix Inc. | Image sensing device |
GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
WO2018175302A1 (fr) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Conjugués polymères ciblant c-src à exposition réduite |
EP3600440A1 (fr) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Conjugués d'exposition réduite modulant des cibles thérapeutiques |
GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
US3544571A (en) | 1968-09-04 | 1970-12-01 | Merck & Co Inc | Process for making pyrazinoylthiourea compounds |
US4246406A (en) | 1979-03-27 | 1981-01-20 | Merck & Co., Inc. | Heterocyclic substituted pyrazinoylguanidines |
JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
WO1993019750A1 (fr) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Composes efficaces dans le traitement de maladies allergiques ou inflammatoires |
US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
KR100439358B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ccr5 길항제로서 유용한 피페라진 유도체 |
HUP0203528A3 (en) | 1999-05-04 | 2003-11-28 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
PT1196396E (pt) * | 1999-07-19 | 2008-05-14 | Univ North Carolina | Compostos farmacologicamente activos com dois princípios activos covalentemente ligados (bloqueador dos canais do sódio/agonista do receptor p2y2) para o tratamento de superfícies mucosas |
EA006685B1 (ru) | 1999-08-21 | 2006-02-24 | Алтана Фарма Аг | Синергетическая композиция |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
ES2213703T5 (es) | 2000-06-27 | 2011-11-02 | Laboratorios S.A.L.V.A.T., S.A. | Carbamatos derivados de arilalquilaminas. |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
WO2002012265A1 (fr) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1345937B1 (fr) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3 |
ES2266291T3 (es) | 2000-12-28 | 2007-03-01 | Almirall Prodesfarma Ag | Nuevos derivados de quinuclidina y composiciones medicinales que los contienen. |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
EP2327765B1 (fr) | 2001-06-21 | 2015-04-01 | BASF Enzymes LLC | Nitralases |
PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
US7361668B2 (en) | 2001-10-17 | 2008-04-22 | Ucb, S.A. | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
CN1832948B (zh) | 2001-12-20 | 2011-06-15 | 基耶西药品股份公司 | 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途 |
WO2003072592A1 (fr) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17 alpha esters cycloalkyle/cycloalcenyle d'alkyle ou haloalkyle-androst-4-en-3-on-11 beta, 17 alpha-diol 17 beta-carboxylates comme agents anti-inflammatoires |
WO2003062259A2 (fr) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Nouveaux composes |
GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
WO2003082787A1 (fr) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations |
DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
EP1507754A1 (fr) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Agonistes du recepteur adrenergique beta 2 alcoxy aryle |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
DE60312520T2 (de) | 2002-06-25 | 2007-11-22 | Merck Frosst Canada Ltd., Kirkland | 8-(biaryl)chinolin-pde4-inhibitoren |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
WO2004005258A1 (fr) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Ethane pyridone a substitution diaryle, inhibiteurs d'enzyme pde4 |
PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
CA2494643A1 (fr) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Derives de n-oxyde de piperidine |
AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
JP4555684B2 (ja) | 2002-08-10 | 2010-10-06 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン |
US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
US20060116518A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel phenanthridines |
PL373598A1 (en) | 2002-08-17 | 2005-09-05 | Altana Pharma Ag | Novel benzonaphthyridines |
SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
EP1532113B1 (fr) | 2002-08-21 | 2008-08-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations |
EP1534675B1 (fr) | 2002-08-23 | 2009-02-25 | Ranbaxy Laboratories, Ltd. | Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine |
KR20050036982A (ko) | 2002-08-29 | 2005-04-20 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체 |
ES2281658T3 (es) | 2002-08-29 | 2007-10-01 | Nycomed Gmbh | 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4. |
WO2004019944A1 (fr) | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines utilisees comme inhibiteurs de pde-4 |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
CN1688577A (zh) | 2002-09-18 | 2005-10-26 | 小野药品工业株式会社 | 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物 |
WO2004026248A2 (fr) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide |
JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
KR20050047552A (ko) | 2002-10-11 | 2005-05-20 | 화이자 인코포레이티드 | 베타-2 작용제로서의 인돌 유도체 |
EP1440966A1 (fr) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Dérivés d'indole utilisables pour traiter des maladies |
US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
EP1554262B1 (fr) | 2002-10-23 | 2007-12-05 | Glenmark Pharmaceuticals Limited | Nouveaux composes tricycliques utiles pour traiter les troubles inflammatoires et allergiques, procede de preparation de ces composes et compositions pharmaceutiques les contenant |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
EP1460064A1 (fr) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Derivés de Indole-2-carboxamide comme beta-2 agonistes |
US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
EP1646615B1 (fr) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp |
CA2528851A1 (fr) | 2003-06-10 | 2004-12-16 | Ace Biosciences A/S | Polypeptides d'aspergillus extracellulaires |
US7317013B2 (en) * | 2003-08-18 | 2008-01-08 | Parion Sciences, Inc. | Cyclic pyrazinoylguanidine sodium channel blockers |
KR20060115348A (ko) * | 2003-08-18 | 2006-11-08 | 패리온 사이언스 인코퍼레이티드 | 지방족 피라지노일구아니딘 나트륨 채널 차단제 |
WO2005026137A2 (fr) | 2003-09-06 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs a cassette de liaison a l'atp |
CN1886393A (zh) | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp-结合弹夹转运蛋白的调控剂 |
US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
EP3219709B1 (fr) | 2004-01-30 | 2020-03-18 | Vertex Pharmaceuticals Incorporated | Composé intermédiaire de modulateurs de transporteurs de cassette à liaison atp |
AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
EP2363128B1 (fr) | 2005-03-11 | 2016-02-17 | Vertex Pharmaceuticals Incorporated | Indoles, modulateurs des transporteurs de la cassette de liaison à l ATP |
AU2006227833A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
US8822451B2 (en) | 2005-05-24 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2007021982A2 (fr) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique |
-
2008
- 2008-05-05 ES ES08759419T patent/ES2361595T3/es active Active
- 2008-05-05 JP JP2010506915A patent/JP5244904B2/ja not_active Expired - Fee Related
- 2008-05-05 AT AT08759419T patent/ATE499363T1/de active
- 2008-05-05 PE PE2008000782A patent/PE20090733A1/es not_active Application Discontinuation
- 2008-05-05 EP EP11152559A patent/EP2332933A1/fr not_active Withdrawn
- 2008-05-05 WO PCT/EP2008/055497 patent/WO2008135557A1/fr active Application Filing
- 2008-05-05 EA EA200901489A patent/EA200901489A1/ru unknown
- 2008-05-05 CA CA002685546A patent/CA2685546A1/fr not_active Abandoned
- 2008-05-05 MX MX2009012077A patent/MX2009012077A/es active IP Right Grant
- 2008-05-05 KR KR1020097025395A patent/KR20100005730A/ko active IP Right Grant
- 2008-05-05 EP EP08759419A patent/EP2155721B1/fr active Active
- 2008-05-05 CN CN2008800226814A patent/CN101687851B/zh not_active Expired - Fee Related
- 2008-05-05 NZ NZ580737A patent/NZ580737A/en not_active IP Right Cessation
- 2008-05-05 AU AU2008248598A patent/AU2008248598B2/en not_active Ceased
- 2008-05-05 PT PT08759419T patent/PT2155721E/pt unknown
- 2008-05-05 BR BRPI0811562-1A2A patent/BRPI0811562A2/pt not_active IP Right Cessation
- 2008-05-05 US US12/451,152 patent/US8318935B2/en not_active Expired - Fee Related
- 2008-05-05 PL PL08759419T patent/PL2155721T3/pl unknown
- 2008-05-05 DE DE602008005140T patent/DE602008005140D1/de active Active
- 2008-05-06 TW TW097116687A patent/TWI351402B/zh not_active IP Right Cessation
- 2008-05-06 AR ARP080101913A patent/AR066458A1/es not_active Application Discontinuation
- 2008-05-06 CL CL2008001301A patent/CL2008001301A1/es unknown
-
2009
- 2009-10-26 ZA ZA200907491A patent/ZA200907491B/xx unknown
- 2009-10-29 IL IL201828A patent/IL201828A0/en unknown
- 2009-11-04 CR CR11091A patent/CR11091A/es unknown
- 2009-11-05 GT GT200900289A patent/GT200900289A/es unknown
- 2009-11-06 HN HN2009003214A patent/HN2009003214A/es unknown
- 2009-11-06 CO CO09125992A patent/CO6290667A2/es not_active Application Discontinuation
- 2009-11-06 TN TNP2009000469A patent/TN2009000469A1/fr unknown
- 2009-11-06 SV SV2009003406A patent/SV2009003406A/es active IP Right Grant
- 2009-11-06 EC EC2009009718A patent/ECSP099718A/es unknown
- 2009-11-30 MA MA32385A patent/MA31400B1/fr unknown
-
2010
- 2010-08-13 HK HK10107723.7A patent/HK1141285A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31400B1 (fr) | Composes organiques | |
MA54327B1 (fr) | Inhibiteurs de kras g12c | |
MA45920B1 (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
TW200745086A (en) | Organic compounds | |
DE602004007808D1 (de) | Neue gamma secretase inhibitoren | |
MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MA31873B1 (fr) | Inhibiteurs de la peptide déformylase | |
TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
MA30652B1 (fr) | Composes organiques | |
MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
DE602004026053D1 (fr) | ||
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
EP1861399A4 (fr) | Antagonistes du recepteur du cgrp | |
IS7928A (is) | Sertakónasóllyfjablöndur til notkunar í leggöng | |
EP1615914A4 (fr) | Antagonistes des recepteurs de cgrp | |
MXPA05008126A (es) | Inhibidores de girasa y uso de los mismos. | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
DE602006003432D1 (de) | Latoren des androgenrezeptors | |
MA29926B1 (fr) | Derives de pyrazine | |
MX2008002234A (es) | Inhibidores de sulfonamida n-biciclico puenteados de gamma secretasa. | |
TNSN06370A1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
PA8601001A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
MXPA05012837A (es) | Inhibidores de caspasa y usos de los mismos. |